{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:03:37Z","timestamp":1761487417413},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p>Despite advances in the treatment of HIV disease, the incidence and mortality of invasive cryptococcal disease remain significant. A matched, case\u2010control study was performed to examine the impact of highly active antiretroviral therapy (HAART) and azole use on the incidence of invasive cryptococcal disease in HIV\u2010infected patients. The study was performed at a metropolitan hospital with a large indigent population and an incidence of seven cases of cryptococcal disease per 1000 persons with AIDS. Bivariate analysis, matched on CD4 count, revealed that both HAART use [odds ratio (OR) 0.43; 95% confidence interval (CI) 0.23\u20130.99] and azole use (OR 0.14; 95% CI 0.06\u20130.34) had a protective effect. Conditional logistic regression stratified on CD4 lymphocyte count revealed a protective role for azole use (OR 0.15; 95% CI 0.06\u20130.40) but not for HAART use (OR 0.47; 95% CI 0.18\u20131.26). Of note, the prevalence of HAART use was low in both cases and controls, with only 12% of cases and 23% of controls on HAART. The results of this study support previous evidence that azole use prevents invasive cryptococcal disease. Although current guidelines for the prophylaxis of opportunistic infections do not suggest routine prophylaxis for cryptococcal infection, this issue should be reconsidered, especially in populations that have a low prevalence of HAART use.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2005.00289.x","type":"journal-article","created":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T17:21:05Z","timestamp":1120238465000},"page":"253-259","source":"Crossref","is-referenced-by-count":4,"title":["Prevention of cryptococcosis in HIV\u2010infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis"],"prefix":"10.1111","volume":"6","author":[{"given":"PT","family":"Cantey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DS","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Rimland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.5.837"},{"key":"e_1_2_6_3_2","first-page":"475","article-title":"Neurological manifestations of the acquired immunodeficiency syndrome (AIDS)","volume":"62","author":"Levy RM","year":"1985","journal-title":"experience at UCSF and review of the literature"},{"key":"e_1_2_6_4_2","first-page":"449","article-title":"Cryptococcosis","volume":"179","author":"Hajjeh RA","year":"1999","journal-title":"population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00036-3"},{"key":"e_1_2_6_6_2","first-page":"206","article-title":"Decline in the incidence of cryptococcosis among HIV\u2010infected patients","volume":"9","author":"McNeil JI","year":"1995","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"e_1_2_6_7_2","first-page":"303","article-title":"Emergence of cryptococcal disease","volume":"17","author":"Hajjeh RA","year":"1995","journal-title":"epidemiologic perspectives 100 years after its discovery"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.4.624"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909213211205"},{"key":"e_1_2_6_10_2","first-page":"51","article-title":"Cryptococcosis in Denmark","volume":"29","author":"Knudsen JD","year":"1997","journal-title":"an analysis of 28 cases in 1988\u201393"},{"key":"e_1_2_6_11_2","first-page":"82","article-title":"Epidemiology of cryptococcosis in France","volume":"23","author":"Dromer F","year":"1996","journal-title":"a 9-year survey (1985\u201393)"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/313992"},{"key":"e_1_2_6_13_2","first-page":"257","article-title":"HIV\u2010associated neurologic disease incidence changes","volume":"56","author":"Sacktor N","year":"2001","journal-title":"Multicenter AIDS Cohort Study, 1990\u201398"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012010-00019"},{"key":"e_1_2_6_15_2","first-page":"555","article-title":"Epidemiology of HIV\u2010associated cryptococcosis in France (1985\u20132001)","volume":"18","author":"Dromer F","year":"2004","journal-title":"comparison of the pre- and post-HAART eras"},{"key":"e_1_2_6_16_2","first-page":"1931","article-title":"Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994\u201397","volume":"12","author":"Holtzer CD","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310926"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90465-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199705000-00016"},{"key":"e_1_2_6_20_2","first-page":"1286","article-title":"Weekly fluconazole for the suppression of recurrent thrush in HIV\u2010seropositive patients","volume":"9","author":"Newton JA","year":"1995","journal-title":"impact on the incidence of disseminated cryptococcal infection"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503163321102"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.827"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/339680"},{"key":"e_1_2_6_24_2","first-page":"1329","article-title":"Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus\u2010infected patients treated with highly active antiretroviral therapy","volume":"36","author":"Vinhagool A","year":"2003","journal-title":"a prospective multi-center, randomized study"},{"key":"e_1_2_6_25_2","first-page":"565","article-title":"Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy","volume":"38","author":"Mussino C","year":"2004","journal-title":"an international observational study"},{"key":"e_1_2_6_26_2","first-page":"955","article-title":"Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994\u201398","volume":"32","author":"Chariyalertsak S","year":"2001","journal-title":"regional variation and temporal trends"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392606"},{"key":"e_1_2_6_28_2","first-page":"789","article-title":"The changing epidemiology of cryptococcosis","volume":"36","author":"Mirza SA","year":"2003","journal-title":"an update from population-based active surveillance from 2 large metropolitan areas 1992\u20132000"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707033370103"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260202"},{"key":"e_1_2_6_31_2","volume-title":"Stepping Back from the Edge: the Pursuit of Antiretroviral Therapy in Botswana, South Africa, and Uganda. UNAIDS Best Practice Collection","author":"UNAIDS.","year":"2003"},{"key":"e_1_2_6_32_2","first-page":"1","article-title":"Guidelines for Preventing Opportunistic Infections Among HIV\u2010Infected Persons \u2013 2002 Recommendations of the US Public Health Service and the Infectious Diseases Society of America","volume":"51","author":"Centers for Disease Control and Prevention.","year":"2002","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111230-00026"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/517056"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.2.217"},{"key":"e_1_2_6_36_2","first-page":"3065","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States","volume":"45","author":"Brandt ME","year":"2001","journal-title":"1992\u201394 and 1996\u201398"},{"key":"e_1_2_6_37_2","first-page":"683","article-title":"Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India","volume":"52","author":"Datta K","year":"2003","journal-title":"a need for care"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1136-2"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/515018"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00201.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.130"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00289.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00289.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:22:13Z","timestamp":1696951333000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00289.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00289.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00289.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}